Adalimumab, etanercept, infliximab and abatacept for treating moderate rheumatoid arthritis after conventional DMARDs have failed
Technology appraisal guidance
Reference number: TA715
Published:
Due to operational reasons, there will be a slight delay to the start of the appraisal. We are aiming to send out the Invitation to Participate in early April 2020 with an anticipated evidence submission deadline to NICE in May 2020.